Other novel HF therapies include omecamtiv mecarbil, a selective cardiac myosin activator, and vericiguat, a sGC stimulator, which demonstrated to improve cardiovascular outcomes and potentially ameliorate ventricular remodeling in HF of both ischemic and non-ischemic etiology. The gene discussed is SGCB; the disease is hydrops fetalis.